Hepcinat Plus Tablets — Daclatasvir + Sofosbuvir 60+400 mg (28 Tabs)
Hepcinat Plus is an advanced combined direct-acting antiviral (DAA) medication for the treatment of chronic Hepatitis C. Each tablet contains a potent combination of Daclatsvir (60 mg) and Sofosbuvir (400 mg). This dual-action formula targets the virus by inhibiting both NS5B and NS5A enzymes, which completely halts viral replication and clears the infection from the body.
Manufacturer: Natco Pharma Ltd. (India). 🇮🇳 Manufactured under license according to international quality standards, Hepcinat Plus provides a cure rate (Sustained Virologic Response) of 95–99% across a wide range of patient profiles, including those who have failed previous interferon-based treatments.
Key Features:
- ✅ Pangenotypic Potential: Highly effective against major Hepatitis C genotypes (1, 2, 3, and 4).
- ✅ 2-in-1 Convenience: Eliminates the need for multiple separate pills, combining the full daily therapeutic dose into one Hepcinat Plus tablet.
- ✅ High Tolerability: Significantly fewer side effects compared to older treatment regimens.
Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 09.04.2026
What Customers Say
No reviews yet
Your review can be the first!